Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 17/20 | 0.59 |
| ▸ | CDK2 | P24941 | 17/20 | 0.59 |
| ▸ | CCNA1 | P78396 | 13/20 | 0.59 |
| ▸ | CDK4 | P11802 | 4/20 | 0.59 |
| ▸ | CCND3 | P30281 | 4/20 | 0.59 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.59 |
| ▸ | TTK | P33981 | 4/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 5/20 | 0.43 |
| ▸ | PLK1 | P53350 | 3/20 | 0.42 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.42 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559150 | 0.94 | CCNA2 (0.66) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL12498641 | 0.87 | CCNA2 (0.59) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL12698383 | 0.85 | CCNA2 (0.57) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL12698384 | 0.85 | CCNA2 (0.56) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL12499970 | 0.84 | CCNA2 (0.55) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL3503406 | 0.83 | CDK2 (0.54) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL12698421 | 0.83 | CCNA2 (0.64) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL3504465 | 0.82 | CDK2 (0.54) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL11022675 | 0.82 | CCNA2 (0.68) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL3504377 | 0.82 | CDK2 (0.53) | CCNA2CDK2CCNA1CDK4CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668188-B1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-05-18 | — | — | EP | disclosed |
| US-8916577-B2 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-23 | — | — | US | disclosed |
| US-8916577-B2 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-23 | — | — | US | disclosed |
| US-8916577-B2 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-23 | — | — | US | disclosed |
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-14 | — | — | US | disclosed |
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-14 | — | — | US | disclosed |
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-14 | — | — | US | disclosed |
| WO-2012101029-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | CDK1, MAP3K1, MAP3K20 | CCNA2 239/4885CDK2 16/4885CCNA1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.